Business · 1 sources covering this

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·1h ago
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/1f2b18ec39a698e4d8a45bd290a2849da873c235"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid"></iframe>

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

How 1 sources are covering this

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

More from Business

SoftBank shares plunge over 11% amid broader tech sell-off

SpaceX sets price as it aims for world's largest stock market debut

Bitcoin's high-conviction holders are turning into sellers as the crypto's price hits new lows

Finland's president says EU should expand to 40 states — including Canada

Reader

Trust & legal

Across the network